Biotech News

Novan Provides Corporate Update and Reports Third Quarter 2021 Financial Results

Novan (NOVN)Novan2026-06-25 13:46 ESTEarnings

- Company executing on plans for three potential New Drug Application (NDA) filings in three years with the first submission targeted in Q3 2022 for lead program SB206 in molluscum contagiosum -

- Advancing priority development pipeline assets by progressing SB019, for the treatment of SARS-CoV-2, toward a...

Open original release

Related news

NOVNNovan2026-06-25 13:46 EST

Novan Engages Syneos Health as Commercial Solutions Provider for SB206

NOVNNovan2026-06-25 13:46 EST

Novan Announces Strategic Priorities and Outlines Key Milestones

NOVNNovan2026-06-25 13:46 EST

Novan to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

NOVNNovan2026-06-25 13:46 EST

Novan Reports Safety Data from B-SIMPLE4 Pivotal Phase 3 Study of SB206

NOVNNovan2026-06-25 13:46 EST

Novan Appoints Brian M. Johnson as Chief Commercial Officer and Receives Conditional FDA Acceptance of Proposed Brand Name KINSOLUS™ for SB206 in Molluscum Contagiosum

NOVNNovan2026-06-25 13:46 EST

Novan to Report Third Quarter 2021 Financial Results on November 10, 2021

NOVNNovan2026-06-25 13:46 EST

Novan Announces Fireside Chat Hosted by Jonathan Aschoff, Ph.D. of ROTH Capital Partners

NOVNNovan2026-06-25 13:46 EST

Novan Announces Favorable Preclinical Safety Data and Intent to Advance SB019 for Treatment of COVID-19

NOVNNovan2026-06-25 13:46 EST

Novan to Participate in the Virtual Investor Roundtable Event

NOVNNovan2026-06-25 13:46 EST

Novan Announces Presentation of Two Posters at the 2022 Winter Clinical Dermatology Conference

View all latest news

Novan

Novan is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

NOVNNovan2026-06-26 09:24 EST

Novan Engages Syneos Health as Commercial Solutions Provider for SB206

NOVNNovan2026-06-26 09:24 EST

Novan Announces Strategic Priorities and Outlines Key Milestones

NOVNNovan2026-06-26 09:24 EST

Novan to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

NOVNNovan2026-06-26 09:24 EST

Novan Reports Safety Data from B-SIMPLE4 Pivotal Phase 3 Study of SB206

NOVNNovan2026-06-26 09:24 EST

Novan Appoints Brian M. Johnson as Chief Commercial Officer and Receives Conditional FDA Acceptance of Proposed Brand Name KINSOLUS™ for SB206 in Molluscum Contagiosum

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States